Incyte Corporation
INCYBiotechnology
$120.39+3.07%As of Oct 30vs prior close
- Market cap
- $24.5B
- P/E (TTM)
- 57.6×
- P/E (FY1)
- 38.8×
- From 52W high
- −7.34%
- EPS (LTM)
- $1.88
- Revenue (LTM)
- $6B
- Net margin
- 6.71%
- Dividend yield
- 0.00%
Nomior Score
80
Fortified DefenderTop 2% of the scored universe
Growth56
Quality73
Value61
Momentum84
Resilience68
Growth
+18.62%revenue a year over 9 fiscal years
FY16 $1.1BLTM $6B
Connections
Revenue to profitQ3 FY26
The operating loss was 45% of revenue, wider by 78 pts on a year.
Latest resultsthird quarter of 2026
Total revenue rose in the quarter, driven by higher net sales across marketed products, with Opzelura and the hematology and oncology portfolio growing faster than Jakafi. Operating and net results were hit by a large one-time research and development charge tied to the Vega Therapeutics acquisition, which produced a GAAP operating and net loss. Management raised full-year guidance for Opzelura, hematology and oncology net sales, and total net sales.
Who owns it
5funds, 2 tracked portfolios